European Society of Cardiology
Dyslipidaemia 2019
This guideline holds 78 pages.
Summary
Defines aggressive LDL-C targets for high and very high CV risk: <1.4 mmol/L (<55 mg/dL) for very high risk with ≥50% reduction. PCSK9 inhibitors recommended for patients not at target on maximum tolerated statin + ezetimibe. Updated risk calculator SCORE2 for European populations.
How the evidence was graded
Grading system
Class I
Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.
At a glance
- Organisation
- European Society of Cardiology
- Published
- 2019
- Region
- EU
- Language
- English
- Grading system
- Class I
Keywords
- Dyslipidaemia
- LDL cholesterol
- Statins
- PCSK9 inhibitors
- SCORE2
- CV risk
